{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:09:06Z","timestamp":1790111346783,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24 K15757"],"award-info":[{"award-number":["24 K15757"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007683","name":"Nihon University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115148","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:31:53Z","timestamp":1781022713000},"page":"115148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preferential nose-to-brain delivery of phenytoin via an intranasal phenytoin\u2013arginine co-amorphous system"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2730-1297","authenticated-orcid":false,"given":"Taiki","family":"Nagatomo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroteru","family":"Irino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuiko","family":"Kanbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5960-2764","authenticated-orcid":false,"given":"Kanon","family":"Nagasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8272-8481","authenticated-orcid":false,"given":"Naoto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1374-4899","authenticated-orcid":false,"given":"Toyofumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115148_b0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.ejpb.2026.115148_b0130","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s00415-017-8465-4","article-title":"Phenytoin: A step by step insight into its multiple mechanisms of action\u201480years of mechanistic studies in neuropharmacology","volume":"264","author":"Keppel Hesselink","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejpb.2026.115148_b0070","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00415-015-7967-1","article-title":"Cardiovascular adverse effects of phenytoin","volume":"263","author":"Guldiken","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejpb.2026.115148_b0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-2125.1983.tb02163.x","article-title":"Acute effects of intravenous phenytoin on the frequency of inter-ictal spikes in man","volume":"16","author":"Milligan","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115148_b0020","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/pharmaceutics12121167","article-title":"A short review on the intranasal delivery of diazepam for treating acute repetitive seizures","volume":"12","author":"Boddu","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115148_b0155","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of antiseizure medications: From bromide salts to Cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejpb.2026.115148_b0180","unstructured":"Pfizer Laboratories Division, 2011. Dilantin (phenytoin sodium) injection, USP. U.S. Food Drug Adm. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/010151s036lbl.pdf. Accessed on 25 May 2026."},{"key":"10.1016\/j.ejpb.2026.115148_b0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","article-title":"Lipid nanoparticles for intranasal administration: Application to nose-to-brain delivery","volume":"15","author":"Battaglia","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115148_b0065","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: An efficient and non-invasive route for systemic administration: Focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2026.115148_b0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/neurolint13010007","article-title":"VALTOCO\u00ae (diazepam nasal spray) for the acute treatment of intermittent stereotypic episodes of frequent seizure activity","volume":"13","author":"Cornett","year":"2021","journal-title":"Neurol. Int."},{"key":"10.1016\/j.ejpb.2026.115148_b0040","doi-asserted-by":"crossref","first-page":"38536","DOI":"10.52965\/001c.38536","article-title":"Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review","volume":"10","author":"Cornett","year":"2022","journal-title":"Health Psychol. Res."},{"key":"10.1016\/j.ejpb.2026.115148_b0185","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA), Spydia nasal spray 5 mg \/ 7.5 mg \/ 10 mg package insert, revised December 2025 (2nd version), https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00071731.pdf, Accessed on 25 May 2026. (in Japanese)."},{"key":"10.1016\/j.ejpb.2026.115148_b0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3390\/pharmaceutics16040481","article-title":"Nasal delivery to the brain: Harnessing nanoparticles for effective drug transport","volume":"16","author":"Gandhi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115148_b0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jconrel.2023.12.054","article-title":"Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases","volume":"366","author":"Huang","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115148_b0175","doi-asserted-by":"crossref","unstructured":"Patharapankal, E.J., A.L.A., Mattern, C., Trivedi, V., 2024. Nose-to-brain (N2B) delivery: An alternative route for the delivery of biologics in the management and treatment of central nervous system disorders. Pharmaceutics. 16, 66. https:\/\/doi.org\/10.3390\/pharmaceutics16010066.","DOI":"10.3390\/pharmaceutics16010066"},{"key":"10.1016\/j.ejpb.2026.115148_b0025","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: A transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejpb.2026.115148_b0215","article-title":"First-in-human positron emission tomography study of intranasal insulin in aging and MCI","volume":"11","author":"Sai","year":"2025","journal-title":"Alzheimers Dement. (n y)"},{"key":"10.1016\/j.ejpb.2026.115148_b0100","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.yebeh.2015.04.027","article-title":"Intranasal therapies for acute seizures","volume":"49","author":"K\u00e4lvi\u00e4inen","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.ejpb.2026.115148_b0125","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: Opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2026.115148_b0230","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1248\/bpb.b16-00787","article-title":"Nasal drug absorption from powder formulations: Effect of fluid volume changes on the mucosal surface","volume":"40","author":"Tanaka","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2026.115148_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114942","article-title":"Inclusion complex of carbamazepine and hydroxypropyl-beta-cyclodextrin enhances nose-to-brain delivery via improved solubility","volume":"218","author":"Totoki","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0095","doi-asserted-by":"crossref","first-page":"19116","DOI":"10.1021\/acsomega.9b02383","article-title":"Critical excipient properties for the dissolution enhancement of phenytoin","volume":"4","author":"Johnson","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejpb.2026.115148_b0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.physbeh.2012.12.007","article-title":"Size of nostril opening as a measure of intranasal volume","volume":"110\u2013111","author":"Schriever","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejpb.2026.115148_b0190","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/pharmaceutics14030588","article-title":"Strategies to improve drug strength in nasal preparations for brain delivery of low aqueous solubility drugs","volume":"14","author":"Pires","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115148_b0210","first-page":"74","article-title":"Stability of phenytoin sodium suspensions for the treatment of open wounds","volume":"10","author":"Rhodes","year":"2006","journal-title":"Int. J. Pharm. Compd."},{"key":"10.1016\/j.ejpb.2026.115148_b0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijpharm.2017.09.020","article-title":"Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling: Enhanced physical stability, dissolution and pharmacokinetic profile","volume":"532","author":"Moinuddin","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0245","article-title":"Exploring the utility of co-amorphous materials to concurrently improve the solubility and permeability of fexofenadine","volume":"72","author":"Uppala","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115148_b0005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/03639045.2017.1411941","article-title":"Brain-targeted intranasal zaleplon solid dispersion in hydrophilic carrier system; 23 full-factorial design and in vivo determination of GABA neurotransmitter","volume":"44","author":"Abd-Elrasheed","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0200","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1080\/03639045.2017.1321659","article-title":"Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery","volume":"43","author":"Pozzoli","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejpb.2023.02.012","article-title":"Improved drug transfer into brain tissue via the \u201cnose-to-brain\u201d approach using suspension or powder formulations based on the amorphous solid dispersion technique","volume":"185","author":"Suwabe","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0170","article-title":"Impact of using amorphous solid dispersions on brain and systemic delivery of intranasally administered phenytoin","volume":"111","author":"Nagatomo","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115148_b0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/pharmaceutics13030389","article-title":"Co-amorphous drug formulations in numbers: Recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies","volume":"13","author":"Liu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115148_b0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.apsb.2018.08.002","article-title":"Advances in coamorphous drug delivery systems","volume":"9","author":"Shi","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejpb.2026.115148_b0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejpb.2008.06.022","article-title":"Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation","volume":"71","author":"Chieng","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0255","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1039\/D0RA04890A","article-title":"Preparation and characterisation of PHT-loaded chitosan lecithin nanoparticles for intranasal drug delivery to the brain","volume":"10","author":"Yousfan","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2026.115148_b0260","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12951-024-02405-8","article-title":"Intranasal delivery of phenytoin loaded layered double hydroxide nanoparticles improves therapeutic effect on epileptic seizures","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejpb.2026.115148_b0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10858-014-9862-y","article-title":"PH-dependent random coil (1)H, (13)C, and (15)N chemical shifts of the ionizable amino acids: A guide for protein pK a measurements","volume":"60","author":"Platzer","year":"2014","journal-title":"J. Biomol. NMR"},{"key":"10.1016\/j.ejpb.2026.115148_b0105","article-title":"Novel methods for intranasal administration under inhalation anesthesia to evaluate nose-to-brain drug delivery","volume":"Exp. (141)","author":"Kanazawa","year":"2018","journal-title":"J. Vis."},{"key":"10.1016\/j.ejpb.2026.115148_b0135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2022.03.017","article-title":"Nose-to-brain\/spinal cord delivery kinetics of liposomes with different surface properties","volume":"344","author":"Kurano","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115148_b0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejps.2016.08.022","article-title":"Development of a screening method for co-amorphous formulations of drugs and amino acids","volume":"95","author":"Kasten","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115148_b0075","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1021\/acs.molpharmaceut.3c00226","article-title":"Designing a novel coamorphous salt formulation of telmisartan with amlodipine to enhance permeability and oral absorption","volume":"20","author":"Hatanaka","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0145","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejpb.2013.03.014","article-title":"Amino acids as co-amorphous stabilizers for poorly water soluble drugs\u2014Part 1: Preparation, stability and dissolution enhancement","volume":"85","author":"L\u00f6bmann","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2016.06.020","article-title":"Influence of variation in molar ratio on co-amorphous drug-amino acid systems","volume":"107","author":"Jensen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0150","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/mp2002973","article-title":"Coamorphous drug systems: Enhanced physical stability and dissolution rate of indomethacin and naproxen","volume":"8","author":"L\u00f6bmann","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/org6030038","article-title":"Mechanochemical synthesis, spectroscopic characterization and molecular structure of piperidine\u2013phenytoin salt","volume":"6","author":"Amil-Miranda","year":"2025","journal-title":"Organics"},{"key":"10.1016\/j.ejpb.2026.115148_b0120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpb.2018.09.024","article-title":"In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine","volume":"132","author":"Kasten","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0045","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1039\/c2ce26055g","article-title":"Acid\u2013base crystalline complexes and the pKa rule","volume":"14","author":"Cruz-Cabeza","year":"2012","journal-title":"CrstEngComm"},{"key":"10.1016\/j.ejpb.2026.115148_b0110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/pharmaceutics10030098","article-title":"Co-amorphous solid dispersions for solubility and absorption improvement of drugs: Composition, preparation, characterization and formulations for oral delivery","volume":"10","author":"Karagianni","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115148_b0050","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10837450.2023.2194406","article-title":"Characterization of co-amorphous carvedilol-maleic acid system prepared by solvent evaporation","volume":"28","author":"Furuishi","year":"2023","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2026.115148_b0240","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijpharm.2017.12.050","article-title":"Molecular-level elucidation of saccharin-assisted rapid dissolution and high supersaturation level of drug from Eudragit\u00ae E solid dispersion","volume":"538","author":"Ueda","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115148_b0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11095-019-2613-8","article-title":"Direct drug delivery of low-permeable compounds to the central nervous system via intranasal administration in rats and monkeys","volume":"36","author":"Iwasaki","year":"2019","journal-title":"Pharm. Res."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:41:48Z","timestamp":1790109708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S0939641126001694"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115148","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preferential nose-to-brain delivery of phenytoin via an intranasal phenytoin\u2013arginine co-amorphous system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115148"}}